Table 1.
Sociodemographic and clinical characteristics and clinical anxiety and depressive symptoms of the samples
| Variables | No recurrence (N=76) |
Recurrence (N=27) |
|---|---|---|
| N (%) | N (%) | |
| Sex | ||
| Male | 63 (82.9) | 21 (77.8) |
| Female | 13 (17.1) | 6 (22.2) |
| Age | 64.1±10.3 | 68.3±10.3 |
| Medical insurance type | ||
| Urban | 47 (61.8) | 15 (55.6) |
| Rural | 4 (5.3) | 0 (0) |
| Other | 19 (25) | 7 (25.9) |
| Self-paying | 6 (7.9) | 5 (18.5) |
| Marital status | ||
| Unmarried | 2 (2.6) | 2 (7.4) |
| Married | 73 (96.1) | 24 (88.9) |
| Divorced | 0 (0) | 1 (3.7) |
| Widowed | 1 (1.3) | 0 (0) |
| Education | ||
| Primary school | 13 (17.1) | 9 (33.3) |
| Secondary school | 26 (34.2) | 8 (29.6) |
| Junior college | 28 (36.8) | 10 (37) |
| Undergraduate or higher | 9 (11.8) | 0 (0) |
| Chronic pain | ||
| Yes | 19 (25) | 6 (22.2) |
| No | 57 (75) | 21 (77.8) |
| How much do you know about your disease? | ||
| Understanding | 34 (44.7) | 7 (25.9) |
| Intermediate | 35 (46.1) | 15 (55.6) |
| Not understanding | 7 (9.2) | 5 (18.5) |
| Support from the family | ||
| Good | 32 (42.1) | 9 (33.3) |
| Intermediate | 42 (55.3) | 17 (63) |
| Bad | 2 (2.6) | 1 (3.7) |
| Burden of medical expenses on the family | ||
| Heavy | 12 (15.8) | 4 (14.8) |
| Intermediate | 31 (40.8) | 11 (40.7) |
| Light | 33 (43.4) | 12 (44.4) |
| Had hematuria | ||
| Yes | 55 (72.4) | 23 (85.2) |
| No | 21 (27.6) | 4 (14.8) |
| Had bladder irritation | ||
| Yes | 9 (11.8) | 10 (37) |
| No | 67 (88.2) | 17 (63) |
| Had dysuria | ||
| Yes | 7 (9.2) | 1 (3.7) |
| No | 69 (90.8) | 26 (96.3) |
| Initial tumor or recurrent tumor | ||
| Initial | 55 (72.4) | 13 (48.1 |
| Recurrent | 21 (27.6) | 14 (51.2) |
| Size of tumor | ||
| <3 cm | 57 (75.0) | 17 (63.0) |
| ≥3 cm | 19 (25.0) | 10 (37.0) |
| Multiplicity | ||
| 1 | 37 (48.7) | 9 (33.3) |
| 2–7 | 34 (44.7) | 16 (59.3) |
| ≥8 | 5 (6.6) | 2 (7.4) |
| CIS | ||
| Without | 75 (98.7) | 25 (92.6) |
| With | 1 (1.3) | 2 (7.4) |
| Cancer stage | ||
| Ta | 68 (89.5) | 19 (70.4) |
| T1 | 8 (10.5) | 8 (29.6) |
| Histopathological grade | ||
| G1 | 11 (14.5) | 0 (0) |
| G2 | 39 (51.3) | 12 (44.4) |
| G3 | 26 (34.2) | 15 (55.6) |
| AUA risk stratification | ||
| Low-risk | 28 (36.8) | 2 (7.4) |
| Intermediate-risk | 26 (34.2) | 10 (37.0) |
| High-risk | 22 (28.9) | 15 (55.6) |
| HADS-A score | 5.2±3.8 | 6.9±4.1 |
| Clinical anxiety symptom | ||
| Yes | 17 (22.4) | 12 (44.4) |
| No | 59 (77.6) | 15 (55.6) |
| HADS-D score | 5.1±4.0 | 8.5±4.7 |
| Clinical depressive symptom | ||
| Yes | 18 (23.7) | 16 (59.3) |
| No | 58 (76.3) | 11 (40.7) |
Its risk stratification and guidelines for NMIBC are the most widely accepted. AUA risk stratification divides NMIBC into low-, intermediate- and high-risk groups and provides a therapeutic regimen for each risk stratification. In bladder cancer, CIS is a flat lesion of the bladder urothelium and a documented precursor of invasive cancer. According to the AUA, all NMIBC cases with CIS are defined as high-risk. NA: not applicable, AUA: American Urological Association, NMIBC: non-muscle invasive bladder cancer, CIS: carcinoma in situ